Jan 08, 2024 / 05:45PM GMT
Eric Joseph JPMorgan Chase&Co.-Moderator
All right, so we'll get started here. I'm [Eric Joseph], Senior Biotech Analyst at JPMorgan. Our next presenting company is Akero Therapeutics, and with us to bring us through the story is CEO Andrew Cheng. There is going to be a Q&A session after the presentation. Just raise your hand and we'll bring a mic around. And for folks tuning in via the webcast, feel free to submit questions by clicking the ask-a-question button. With that, Andrew?
Andrew Cheng - Akero Therapeutics Inc - President, Chief Executive Officer, Director
Thank you very much for having us, and we're excited to be back and really to be moving into '24. I think that '23 is an eventful year for us, and it really set us up well for how we're going to be moving forward. So I have to show my Safe Harbor slide to please my legal counsel, but I think that's enough. And so when you think about where we are as a company, we're a clinical-stage Phase 3 company, and that's really exemplified by our press release at the end of last
Akero Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers